Home › NCT06149780
Fractionated 1927-nm Non Ablative Thulium Laser in Treating Post Inflammatory Hyperpigmentation
Efficacy and Safety of the Fractionated 1927-nm Non Ablative Thulium Laser in Treating Post Inflammatory Hyperpigmentation in Skin Phototypes IV-VI
Who can join
Ages 18 and older · All sexes · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: * Patient age 18 and older * Patient with skin phototypes IV-VI * Patient able to understand requirements of the study and risks involved * Patient able to sign a consent form * Patient to have discontinued all oral medications used to treat pigmentary abnormalities and all topical medications, except for sunscreen, used to treat pigmentary abnormalities on the buttocks one month prior to treatment Exclusion Criteria: * A patient who has skin dyspigmentation, birth marks, tattoos, or other skin findings at baseline on either buttock that may obscure study results * A patient who is lactating, pregnant, or planning to become pregnant
About the study
To study the effect of fractionated 1927-nm non ablative thulium laser in reduction of post inflammatory hyperpigmentation (PIH) using a validated and reproducible model for studying PIH.
* Determine if there is aa reduction in PIH in patients treated with three (3) monthly sessions of fractionated 1927-nm non ablative thulium laser * Determine if there is efficacy of post-procedure clobetasol propionate 0.05% ointment in the management of PIH * Determine the histological and molecular changes that occur with laser and laser plus topical steroid treatment compared to untreated skin
What is being tested
- Patients treated with laser (device)
Sponsor: Henry Ford Health System · Participants: 15 · Started: Nov 15, 2023
Contact the study team
- Fanar Razoky, Bachelors · Phone: 313-694-1923
- Mohammad Tasneem, MD · Phone: 313-916-2151
Official record on ClinicalTrials.gov — NCT06149780
Locations in the U.S.
| Michigan | Henry Ford Medical Center, Detroit |
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.